Key result
Nesiritide's safety and efficacy in acute decompensated heart failure, as evaluated in the landmark ASCEND-HF trial, are reviewed along with its potential evolving role in future therapy.
Why the study?
Does nesiritide improve clinical outcomes in patients with acute decompensated heart failure?
Does nesiritide improve clinical outcomes in patients with acute decompensated heart failure?
This review summarizes the findings and lessons learned from the ASCEND-HF trial regarding the use of nesiritide in acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Offers synthesis of ASCEND-HF lessons for ADHF; leaves open nesiritide's potential role pending further trials.
Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.
No takes yet. Share an insight, caveat, or question.
Dandamudi et al. (2012) conducted a review in acute decompensated heart failure. nesiritide was evaluated. Nesiritide's safety and efficacy in acute decompensated heart failure, as evaluated in the landmark ASCEND-HF trial, are reviewed along with its potential evolving role in future therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: